ZA200102714B - Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases. - Google Patents
Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases. Download PDFInfo
- Publication number
- ZA200102714B ZA200102714B ZA200102714A ZA200102714A ZA200102714B ZA 200102714 B ZA200102714 B ZA 200102714B ZA 200102714 A ZA200102714 A ZA 200102714A ZA 200102714 A ZA200102714 A ZA 200102714A ZA 200102714 B ZA200102714 B ZA 200102714B
- Authority
- ZA
- South Africa
- Prior art keywords
- neurotrophic factor
- volume
- pages
- composition
- retinal
- Prior art date
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 title claims description 63
- 102000007072 Nerve Growth Factors Human genes 0.000 title claims description 52
- 239000003900 neurotrophic factor Substances 0.000 title claims description 40
- 208000015122 neurodegenerative disease Diseases 0.000 title description 7
- 230000004770 neurodegeneration Effects 0.000 title description 5
- 239000000203 mixture Substances 0.000 claims description 42
- 210000001525 retina Anatomy 0.000 claims description 20
- MICLTPPSCUXHJT-UHFFFAOYSA-M potassium;4-[3-(6-oxo-3h-purin-9-yl)propanoylamino]benzoate Chemical group [K+].C1=CC(C(=O)[O-])=CC=C1NC(=O)CCN1C(NC=NC2=O)=C2N=C1 MICLTPPSCUXHJT-UHFFFAOYSA-M 0.000 claims description 19
- 238000009472 formulation Methods 0.000 claims description 14
- 201000001119 neuropathy Diseases 0.000 claims description 14
- 230000007823 neuropathy Effects 0.000 claims description 14
- 210000003733 optic disk Anatomy 0.000 claims description 13
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 13
- 230000000699 topical effect Effects 0.000 claims description 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 claims description 4
- 229960001117 clenbuterol Drugs 0.000 claims description 4
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 claims description 4
- 229960004135 idebenone Drugs 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 210000002592 gangliocyte Anatomy 0.000 description 25
- 241000700159 Rattus Species 0.000 description 20
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 19
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 19
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 230000002207 retinal effect Effects 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 230000004083 survival effect Effects 0.000 description 13
- 102000015336 Nerve Growth Factor Human genes 0.000 description 11
- 229940053128 nerve growth factor Drugs 0.000 description 11
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 210000001328 optic nerve Anatomy 0.000 description 9
- 210000003994 retinal ganglion cell Anatomy 0.000 description 8
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 7
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 208000010412 Glaucoma Diseases 0.000 description 6
- RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 101000996663 Homo sapiens Neurotrophin-4 Proteins 0.000 description 5
- 102100033857 Neurotrophin-4 Human genes 0.000 description 5
- 101150056950 Ntrk2 gene Proteins 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 229960002934 propentofylline Drugs 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
- 101150111783 NTRK1 gene Proteins 0.000 description 4
- 206010038923 Retinopathy Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000001228 trophic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YCYMCMYLORLIJX-SNVBAGLBSA-N (2r)-2-propyloctanoic acid Chemical compound CCCCCC[C@H](C(O)=O)CCC YCYMCMYLORLIJX-SNVBAGLBSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 108090000742 Neurotrophin 3 Proteins 0.000 description 3
- 102100029268 Neurotrophin-3 Human genes 0.000 description 3
- 208000017442 Retinal disease Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000000030 antiglaucoma agent Substances 0.000 description 3
- 230000008335 axon cargo transport Effects 0.000 description 3
- 230000003376 axonal effect Effects 0.000 description 3
- 210000005056 cell body Anatomy 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000004410 intraocular pressure Effects 0.000 description 3
- 239000013010 irrigating solution Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101100517381 Rattus norvegicus Ntrk1 gene Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 210000000411 amacrine cell Anatomy 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940082649 blood substitutes and perfusion irrigating solutions Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 229940124274 edetate disodium Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 230000000508 neurotrophic effect Effects 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 201000006366 primary open angle glaucoma Diseases 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229940021384 salt irrigating solution Drugs 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241001133184 Colletotrichum agaves Species 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 101100261976 Drosophila melanogaster trk gene Proteins 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 101100127166 Escherichia coli (strain K12) kefB gene Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- -1 NT-6 Proteins 0.000 description 1
- 101150117329 NTRK3 gene Proteins 0.000 description 1
- 102000003683 Neurotrophin-4 Human genes 0.000 description 1
- 108090000099 Neurotrophin-4 Proteins 0.000 description 1
- 208000021957 Ocular injury Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000030768 Optic nerve injury Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 101100537955 Schizosaccharomyces pombe (strain 972 / ATCC 24843) trk1 gene Proteins 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000008247 brain infarction Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000000298 carbocyanine Substances 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 229940078469 dl- cysteine Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010014606 glutathione-bicarbonate-Ringer solution Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000019581 neuron apoptotic process Effects 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 229940097998 neurotrophin 4 Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000004491 retinal development Effects 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 230000004500 retinal neurogenesis Effects 0.000 description 1
- 210000001116 retinal neuron Anatomy 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000003863 superior colliculi Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 102000015534 trkB Receptor Human genes 0.000 description 1
- 108010064880 trkB Receptor Proteins 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11098398P | 1998-12-03 | 1998-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200102714B true ZA200102714B (en) | 2002-06-03 |
Family
ID=22335984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200102714A ZA200102714B (en) | 1998-12-03 | 2001-04-03 | Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases. |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1135134B1 (es) |
JP (1) | JP2002531405A (es) |
KR (1) | KR100688137B1 (es) |
CN (1) | CN1325308A (es) |
AR (1) | AR022685A1 (es) |
AT (1) | ATE290866T1 (es) |
AU (1) | AU769290B2 (es) |
BR (1) | BR9915803A (es) |
CA (1) | CA2353527C (es) |
DE (1) | DE69924284T2 (es) |
ES (1) | ES2237196T3 (es) |
HK (1) | HK1038510B (es) |
PT (1) | PT1135134E (es) |
TW (1) | TWI246421B (es) |
WO (1) | WO2000032197A1 (es) |
ZA (1) | ZA200102714B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE499103T1 (de) | 2000-07-07 | 2011-03-15 | Spectrum Pharmaceuticals Inc | Verfahren zur behandlung von arzneimittelinduzierter peripherer neuropathie und verwandten krankheitsformen |
US20020156277A1 (en) * | 2001-04-20 | 2002-10-24 | Fick David B. | Synthesis and methods of use of purine analogues and derivatives |
MXPA04001255A (es) * | 2001-08-29 | 2004-05-27 | Alcon Inc | Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma. |
US20060287246A1 (en) * | 2003-09-24 | 2006-12-21 | Shinji Yoneda | Remedy for eye diseases accompanied by optic nerve injuries |
JPWO2006054513A1 (ja) * | 2004-11-19 | 2008-05-29 | キッセイ薬品工業株式会社 | 神経因性疼痛の予防又は治療剤 |
EP1754474A1 (en) * | 2005-02-02 | 2007-02-21 | Eucro European Contract Research GmbH & Co. KG | Use of S-Clenbuterol |
EP2266559A1 (en) | 2005-03-15 | 2010-12-29 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for ophthalmic disease |
ES2588770T3 (es) | 2010-08-16 | 2016-11-04 | Santhera Pharmaceuticals (Schweiz) Ag | Derivados de benzoquinona para el tratamiento de enfermedades oculares mitocondriales |
CN104994845B (zh) * | 2012-10-23 | 2017-11-17 | 尼科斯科学爱尔兰公司 | 用于眼科应用的醌基一氧化氮供体化合物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH059114A (ja) * | 1990-08-29 | 1993-01-19 | Takeda Chem Ind Ltd | 糖尿病性合併症の予防・治療剤 |
US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
US5641750A (en) * | 1995-11-29 | 1997-06-24 | Amgen Inc. | Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product |
US5641749A (en) * | 1995-11-29 | 1997-06-24 | Amgen Inc. | Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product |
US6261545B1 (en) * | 1996-09-13 | 2001-07-17 | Advanced Medicine Research Institute | Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders |
WO1998010758A1 (en) * | 1996-09-13 | 1998-03-19 | The Regents Of The University Of California | Methods for treatment of retinal diseases |
JPH10218787A (ja) * | 1997-02-06 | 1998-08-18 | Akio Okamoto | 神経栄養因子による眼科用組成物 |
-
1999
- 1999-11-23 TW TW088120454A patent/TWI246421B/zh not_active IP Right Cessation
- 1999-12-01 CN CN99813086A patent/CN1325308A/zh active Pending
- 1999-12-01 EP EP99965071A patent/EP1135134B1/en not_active Expired - Lifetime
- 1999-12-01 CA CA002353527A patent/CA2353527C/en not_active Expired - Fee Related
- 1999-12-01 KR KR1020017003178A patent/KR100688137B1/ko not_active IP Right Cessation
- 1999-12-01 AT AT99965071T patent/ATE290866T1/de active
- 1999-12-01 BR BR9915803-5A patent/BR9915803A/pt not_active Application Discontinuation
- 1999-12-01 PT PT99965071T patent/PT1135134E/pt unknown
- 1999-12-01 AU AU31066/00A patent/AU769290B2/en not_active Ceased
- 1999-12-01 JP JP2000584892A patent/JP2002531405A/ja active Pending
- 1999-12-01 ES ES99965071T patent/ES2237196T3/es not_active Expired - Lifetime
- 1999-12-01 WO PCT/US1999/028385 patent/WO2000032197A1/en not_active Application Discontinuation
- 1999-12-01 DE DE69924284T patent/DE69924284T2/de not_active Expired - Lifetime
- 1999-12-02 AR ARP990106130A patent/AR022685A1/es unknown
-
2001
- 2001-04-03 ZA ZA200102714A patent/ZA200102714B/en unknown
-
2002
- 2002-01-08 HK HK02100111.2A patent/HK1038510B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU3106600A (en) | 2000-06-19 |
JP2002531405A (ja) | 2002-09-24 |
HK1038510B (zh) | 2005-05-20 |
KR100688137B1 (ko) | 2007-03-09 |
EP1135134B1 (en) | 2005-03-16 |
CN1325308A (zh) | 2001-12-05 |
ES2237196T3 (es) | 2005-07-16 |
AR022685A1 (es) | 2002-09-04 |
KR20010075055A (ko) | 2001-08-09 |
ATE290866T1 (de) | 2005-04-15 |
DE69924284D1 (de) | 2005-04-21 |
WO2000032197A1 (en) | 2000-06-08 |
TWI246421B (en) | 2006-01-01 |
CA2353527A1 (en) | 2000-06-08 |
CA2353527C (en) | 2007-11-06 |
PT1135134E (pt) | 2005-05-31 |
BR9915803A (pt) | 2001-08-21 |
EP1135134A1 (en) | 2001-09-26 |
DE69924284T2 (de) | 2005-08-04 |
AU769290B2 (en) | 2004-01-22 |
HK1038510A1 (en) | 2002-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2582316C (en) | Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases | |
US20120004274A1 (en) | Use of inhibitors of jun n-terminal kinases to treat glaucoma | |
CA2353527C (en) | Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases | |
US20050203121A1 (en) | Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases | |
AU1506600A (en) | Use of staurosporine derivatives for treating ocular neovascular diseases | |
KR20010083884A (ko) | 눈 질환 치료제 | |
CA2455896A1 (en) | Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma | |
MXPA01002895A (es) | Uso de estimuladores del factor neutrofico para el tratamiento de enfermedades oftalmicas neurodegenerativas | |
US20040162315A1 (en) | Use of compounds for treating conditions resulting from injury to the corneal nerve after LASIK and other ocular surgeries or trauma | |
KR20070019001A (ko) | 안구 신경퇴행성 질환의 치료를 위한 신경성 인자 자극제 | |
AU2002322700A1 (en) | Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma | |
EP0872238B1 (en) | Use of olanzapine for the manufacture of a medicament for neuroprotection | |
US20030022889A1 (en) | Method for providing neuro-protective effects |